Last updated: 2026-09-16 09:04:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Kymera Therapeutics, Inc. (KYMR) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $113.01, with a market capitalisation of $9.53B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $47.86 to $130.05. This page covers its latest market performance, valuation, price trends and company information.
$9.53B | |
$114.50 | |
$130.05 | |
$9.60 | |
$114.63 | |
471.00K | |
858.77K | |
-- | |
$130.05 | |
$47.86 | |
-- | |
-- |
Kymera Therapeutics, Inc. (KYMR) is trading at $116.46 in pre-market trading as of 2026-09-15 23:31:00, up 1.60% ($1.83) from the previous close of $114.63
Pre-market trading shows how investors are pricing KYMR before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Kymera Therapeutics, Inc. (KYMR) moved from $117.39 to $113.01, representing a decline of 3.73% ($4.38).
The stock traded between $109.72 and $123.60 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 640.90 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 79.3%
KYMR is currently trading at $113.01, placing it 79.3% of the way from its 52-week low of $47.86 to its 52-week high of $130.05. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 273 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Kymera Therapeutics, Inc. (KYMR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.